论文信息 - MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer - 字舞流文

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

C. Hudis | J. Baselga | H. Rugo | H. Wildiers | D. Patt | E. Zamora | J. O’Shaughnessy | V. Diéras | D. Yardley | S. Tolaney | J. Cortés | M. Dickler | Martin Frenzel | A. Koustenis